Safety of anti-tumor necrosis factor therapies in arthritis patients

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 17, Issue 3, 2014, Pages 324-361

  Nanau, Radu M ^a   Neuman, Manuela G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; GAMMA GLUTAMYLTRANSFERASE; GOLIMUMAB; HEMOGLOBIN; HISTONE ANTIBODY; IBUPROFEN; INFLIXIMAB; LACTATE DEHYDROGENASE; LEFLUNOMIDE; LIVER ENZYME; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSOME ANTIBODY; PIROXICAM; PLACEBO; PREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ABDUCENS NERVE PARALYSIS; ABSCESS; ACTINOMYCOSIS; ACUTE HEPATITIS; ACUTE KIDNEY FAILURE; ACUTE MOTOR AXONAL NEUROPATHY; ADULT RESPIRATORY DISTRESS SYNDROME; ANAPHYLACTOID PURPURA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIPHOSPHOLIPID SYNDROME; APHASIA; APPLICATION SITE ECZEMA; ARTHRALGIA; ARTHRITIS; ASPERGILLOSIS; ASTHENIA; ASTHMA; ATAXIA; ATAXIC GAIT; ATOPIC DERMATITIS; AUTOIMMUNE HEPATITIS; AUTOIMMUNE LEUKOENCEPHALOPATHY; BALANCE DISORDER; BASAL CELL CARCINOMA; BLASTOMYCOSIS; BLINDNESS; BLOOD TOXICITY; BLURRED VISION; BRADYCARDIA; BRADYKINESIA; BRAIN DISEASE; BULLOUS PEMPHIGOID; BURNING SENSATION; CANDIDIASIS; CARDIOPULMONARY ARREST; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM LUPUS; CERVICAL MYELITIS; CHEST INFECTION; CHEST TIGHTNESS; CHILBLAIN; CHOLESTASIS; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL (TOPIC); CLONUS; COCCIDIOIDOMYCOSIS; COGNITIVE DEFECT; COMA; CONFUSION; CONGESTIVE CARDIOMYOPATHY; COORDINATION DISORDER; COUGHING; CRACKLE; CRYPTOCOCCOSIS; CYTOPENIA; DEMYELINATING DISEASE; DEMYELINATING NEUROPATHY; DERMATITIS; DERMATOMYOSITIS; DIPLOPIA; DISCOID LUPUS ERYTHEMATOSUS; DISSEMINATED INTRAVASCULAR CLOTTING; DRESS SYNDROME; DRUG APPROVAL; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSARTHRIA; DYSPNEA; EDEMA; ENCEPHALITIS; ENTERITIS; EOSINOPHILIA; EPIGASTRIC DISCOMFORT; EPSTEIN BARR VIRUS INFECTION; EYE DISEASE; FACIAL NERVE PARALYSIS; FATTY LIVER; FECES INCONTINENCE; FEVER; FIBROSING ALVEOLITIS; GASTROINTESTINAL INFECTION; GINGIVAL ABSCESS; GRANULOCYTOPENIA; GRANULOMA ANNULARE; GRANULOMATOUS HEPATITIS; GUILLAIN BARRE SYNDROME; HEADACHE; HEART FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEMIPARESIS; HEMOLYTIC ANEMIA; HEMOPHAGOCYTIC SYNDROME; HEMOPTYSIS; HEPATITIS B; HEPATOMEGALY; HERPES ZOSTER; HIGH RISK POPULATION; HILAR ADENOPATHY; HILAR EDENOPATHY; HISTOPLASMOSIS; HODGKIN DISEASE; HOT FLUSH; HUMAN; HYPEREOSINOPHILIA; HYPOTENSION; INFECTION; INFLAMMATION; INFUSION RELATED REACTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE URTICARIA; INTERSTITIAL LUNG DISEASE; INTERSTITIAL NEPHRITIS; INTERSTITIAL PNEUMONIA; JAUNDICE; JOINT SWELLING; LEGIONNAIRE DISEASE; LEUKOCYTE COUNT; LEUKOCYTOCLASTIC VASCULITIS; LEUKOCYTOSIS; LEUKOENCEPHALOPATHY; LEUKOPENIA; LICHEN PLANUS; LICHENOID ERUPTION; LIMB WEAKNESS; LISTERIOSIS; LIVER TOXICITY; LOBAR PNEUMONIA; LOEFFLER PNEUMONIA; LUNG FIBROSIS; LUNG GRANULOMATOSIS; LUNG HEMORRHAGE; LUNG INFECTION; LUNG SARCOIDOSIS; LUNG TOXICITY; LUPUS ERYTHEMATOSUS; LUPUS LIKE SYNDROME; LUPUS VULGARIS; LYMPHADENOPATHY; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MONONEUROPATHY MULTIPLEX; MONOTHERAPY; MORPHEA; MOTOR NEUROPATHY; MOUTH ULCER; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; MYALGIA; MYCOSIS; MYELITIS; MYOCLONUS; MYOPIA; NERVE CONDUCTION DISORDER; NERVE PARALYSIS; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NEUTROPHILIA; NON MELANOMA SKIN CANCER; OCULOMOTORIUS PALSY; OPHTHALMOPLEGIA; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; ORGANIZING PNEUMONIA; OROFACIAL MYOCLONUS; PANCYTOPENIA; PARAPLEGIA; PARESIS; PARESTHESIA; PEMPHIGUS FOLIACEUS; PERIPHERAL NERVE VASCULITIS; PERIPHERAL NEUROPATHY; PETECHIA; PHOTOSENSITIVITY; PLEOCYTOSIS; PNEUMOCYSTIS PNEUMONIA; PNEUMOCYSTOSIS; PNEUMONIA; POLYNEUROPATHY; POLYOMAVIRUS INFECTION; POLYRADICULONEUROPATHY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURIGO; PRURITUS; PSORIASIS; PTOSIS; PUSTULAR PSORIASIS; PUSTULE; QUADRIPLEGIA; RASH; REFLEX DISORDER; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; RESPIRATORY FUNCTION DISORDER; RETICULOCYTOSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SARCOIDOSIS; SCOTOMA; SENSORIMOTOR NEUROPATHY; SENSORY DYSFUNCTION; SKIN ALLERGY; SKIN CANCER; SKIN INFECTION; SKIN LEISHMANIASIS; SKIN LUPUS ERYTHEMATOSUS; SKIN PAIN; SKIN SWELLING; SKIN TINGLING; SKIN TOXICITY; SMALL VESSEL VASCULITIS; SORE THROAT; SPASTIC PARESIS; STEVENS JOHNSON SYNDROME; STRONGYLOIDIASIS; SUBCORNEAL PUSTULAR DERMATOSIS; SUPRAVENTRICULAR TACHYCARDIA; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; TACHYPNEA; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; TOXIC HEPATITIS; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; URTICARIA PIGMENTOSA; VASCULITIS; VIRUS INFECTION; VISCERAL LEISHMANIASIS; VISUAL IMPAIRMENT; WEAKNESS; WELLS SYNDROME; WHITE MATTER LESION; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84905282586     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3wp4f     Document Type: Review

References (256)

1. Neuman MG. Apoptosis in diseases of the liver. Crit Rev Clin Lab Sci. 2001; 38: 109-66.
2. Chung EY, Kim SJ, Ma XJ. Regulation of cytokine production during phagocytosis of apoptotic cells. Cell Res. 2006; 16: 154-61.
3. Frankenberg T, Kirschnek S, Häcker H, Häcker G. Phagocytosis-induced apoptosis of macrophages is linked to uptake, killing and degradation of bacteria. Eur J Immunol. 2008; 38: 204-15.
4. Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, Maini RN, Feldmann M. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest. 1994; 94: 749-60.
5. Maurice MM, van der Graaff WL, Leow A, Breedveld FC, van Lier RA, Verweij CL. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum. 1999; 42: 2166-73.
6. Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. Ann Rheum Dis. 2001; 60: 133-9.
7. Schlüter D, Deckert M. The divergent role of tumor necrosis factor receptors in infectious diseases. Microbes Infect. 2000; 2: 1285-92.
8. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003; 48: 3013-22.
9. Cohen LE, Nanau RM, Delzor F, Neuman MG. Biological Therapies in Inflammatory Bowel Disease. Transl Res. 2014. In press. doi:10. 1016/j. trsl. 2014. 01. 002.
10. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999; 354: 1932-9.
11. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000; 343: 1594-602.
12. St. Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. ArthritisRheum. 2004; 50: 3432-43.
13. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, Rahman MU. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebocontrolled trial. ArthritisRheum. 2006; 54: 1075-86.
14. Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Raychaudhuri A, Mendelsohn A, Martini A, Giannini EH. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007; 56: 3096-106.
15. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebocontrolled trial (ASSERT). Arthritis Rheum. 2005; 52: 582-91.
16. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000; 343: 1586-93.
17. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martín Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004; 363: 675-81.
18. van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, Freundlich B, MacPeek. D. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis. 2006; 65: 1478-83.
19. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008; 372: 375-82.
20. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003; 48: 35-45.
21. Keystone E, Heijde Dv, Mason D Jr, Landewé R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Arthritis Rheum. 2008; 58: 3319-29.
22. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GOFORWARD Study. Ann Rheum Dis. 2009; 68: 789-96.
23. Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, Goel N, Brezinschek HP, Innes A, Strand V. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009; 68: 805-11.
24. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU. Golimumab, a human antitumor necrosis factor alpha monoclonal antibody, injected subcutaneouslyevery four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebocontrolled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009; 60: 2272-83.
25. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GOFORWARD Study. Ann Rheum Dis. 2009; 68: 789-96.
26. Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU. Golimumab in patients with active rheumatoid arthritis after treatment withtumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009; 374: 210-21.
27. Janssen Biotech, Inc. REMICADE® (infliximab). Highlights of Prescribing Information. 2013. http://www. remicade. com/shared/product/remicade/prescribing-information. pdf.
28. AbbVie, Inc. HUMIRA® (adalimumab). Highlights of Prescribing Information. 2013. http://www. rxabbvie. com/pdf/humira. pdf.
29. UCB, Inc. CIMZIA® (certolizumab pegol). Highlights of Prescribing Information. 2012. http://www. cimzia. com/pdf/Prescribing_Information. pdf.
30. Janssen Biotech, Inc. SIMPONI® (golimumab). Highlights of Prescribing Information. 2013. http://www. simponi. com/sites/default/files/pdf/presc ribing-information. pdf.
31. Amgen, Inc. ENBREL® (etanercept). Highlights of Prescribing Information. 2013. http://www. enbrel. com/prescribinginformation. jspx.
32. Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, Cuillerier E, Fautrel B, Michelet C, Morel J, Puéchal X, Wendling D, Lemann M, Ravaud P, Mariette X. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011; 70: 616-23.
33. Mendes D, Alves C, Batel-Marques F. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events. J Clin Pharm Ther. 2014; 39: 307-13.
34. Baddley JW, Winthrop KL, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study. Ann Rheum Dis. 2013. In press. doi: 10. 1136/annrheumdis-2013-203407.
35. Nordgaard-Lassen I, Dahlerup JF, Belard E, Gerstoft J, Kjeldsen J, Kragballe K, Ravn P, Sørensen IJ, Theede K, Tjellesen L. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J. 2012; 59: C4480.
36. Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford). 2011; 50: 222-9.
37. Lee SK, Kim SY, Kim EY, Jung JY, Park MS, Kim YS, Kim SK, Chang J, Kang YA. Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea. Lung. 2013; 191: 565-71.
38. Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, McFarland B, Austin D, Radcliffe L, Suhler E, Choi D, Rosenbaum JT, Herrinton LJ. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis. 2013; 72: 37-42.
39. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010; 69: 522-8.
40. Navarra SV, Tang B, Lu L, Lin HY, Mok CC, Asavatanabodee P, Suwannalai P, Hussein H, Rahman MU. Risk of tuberculosis with anti-tumor necrosis factor-αtherapy: substantially higher number of patients at risk in Asia. Int J Rheum Dis. 2013 In press. doi: 10. 1111/1756-185X. 12188.
41. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004; 350: 2060-2067.
42. Reenaers C, Belaiche J, Louis E. Should patients under long-term anti-TNF therapies be followed for tuberculosis contamination? Inflamm Bowel Dis. 2010; 16: 1271-2.
43. Hatemi G, Melikoglu M, Ozbakir F, Tascilar K, Yazici H. Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists. Arthritis Res Ther. 2012; 14: R147.
44. Ke WM, Chen LS, Parng IM, Chen WW, On AW. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan. Int J Tuberc Lung Dis. 2013; 17: 1590-5.
45. Malaviya AN, Kapoor S, Garg S, Rawat R, Shankar S, Nagpal S, Khanna D, Furst DE. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factoralpha inhibitors in India--An audit report. J Rheumatol. 2009; 36: 1414-20.
46. Mankia S, Peters JE, Kang S, Moore S, Ehrenstein MR. Tuberculosis and anti-TNF treatment: experience of a central London hospital. Clin Rheumatol. 2011; 30: 399-401.
47. Arend SM, Leyten EM, Franken WP, Huisman EM, van Dissel JT. A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin Infect Dis. 2007; 45: 1470-5.
48. Hernández MV, Meineri M, Sanmartí R. Skin lesions and treatment with tumor necrosis factor alpha antagonists. Reumatol Clin. 2013; 9: 53-61.
49. Peña-Sagredo JL, Hernández MV, Fernandez-Llanio N, Giménez-Ubeda E, Muñoz-Fernandez S, Ortiz A, Gonzalez-Gay MA, Fariñas MC. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. Clin Exp Rheumatol. 2008; 26: 854-9.
50. Lanternier F, Tubach F, Ravaud P, Salmon D, Dellamonica P, Bretagne S, Couret M, Bouvard B, Debandt M, Gueit I, Gendre JP, Leone J, Nicolas N, Che D, Mariette X, Lortholary O. Incidence and Risk Factors of Legionella pneumophila Pneumonia During Anti-Tumor Necrosis Factor Therapy: A Prospective French Study. Chest. 2013; 144: 990-8.
51. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008; 83: 181-94.
52. Wissmann G, Morilla R, Martín-Garrido I, Friaza V, Respaldiza N, Povedano J, Praena-Fernández JM, Montes-Cano MA, Medrano FJ, Goldani LZ, de la Horra C, Varela JM, Calderón EJ. Pneumocystis jirovecii colonization in patients treated with infliximab. Eur J Clin Invest. 2011; 41: 343-8.
53. Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 2007; 52: 1481-4.
54. Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, Tesser J, Posever J, Miller M, Araujo J, Kageyama DM, Berry M, Karl L, Yung CM. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum. 2004; 50: 1959-66.
55. Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-αinhibitors: systematic review of the literature. Clin Infect Dis. 2013; 57: 1318-30.
56. Pérez-Alvarez R, Díaz-Lagares C, GarcíaHernández F, Lopez-Roses L, Brito-Zerón P, Pérezde-Lis M, Retamozo S, Bové A, Bosch X, SanchezTapias JM, Forns X, Ramos-Casals M. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011; 90: 359-71.
57. Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, Motomura S. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011; 21: 16-23.
58. Oshima Y, Tsukamoto H, Tojo A. Association of hepatitis B with antirheumatic drugs: a case-control study. Mod Rheumatol. 2013; 23: 694-704.
59. Zhang X, Zhang F, Wu D, Bao C, Zhu P, Zhang X, Huang C, He D, Tao Y, Fang Y, Gu J, Wu H, Sun L, Yang X, Huang F, Xu H, Zhao D, Zhang M, Zheng Y, Li Z. Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus. Int J Rheum Dis. 2013; 16: 408-12.
60. Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, SarziPuttini P. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010; 62: 749-54.
61. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, Manesis EK, Archimandritis AI. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010; 69: 1352-5.
62. Serac G, Tubach F, Mariette X, Salmon-Céron D, Ravaud P, Lioté F, Laharie D, Ziza JM, Marguerie L, Bonnet C, Falgarone G, Nicolas N, Lortholary O, Chosidow O. Risk of herpes zoster in patients receiving anti-TNF-αin the prospective French RATIO registry. J Invest Dermatol. 2012; 132: 726-9.
63. Balandraud N, Guis S, Meynard JB, Auger I, Roudier J, Roudier C. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increaseEpstein-Barr virus load in patients with rheumatoid arthritis. Arthritis Rheum. 2007; 57: 762-7.
64. Hernández MV, Sanmartí R, Cañete JD, Descalzo MA, Alsina M, Carmona L, Gomez-Reino JJ. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res (Hoboken). 2013; 65: 2024-31.
65. Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol. 2011; 7: 55-63.
66. Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, Romagnani S, Maggi E. Antiinfliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2010; 65: 657-61.
67. Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008; 159: 527-36.
68. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009; 124: 1259-66.
69. Puxeddu I, Giori L, Rocchi V, Bazzichi L, Bombardieri S, Tavoni A, Migliorini P, Del Corso I. Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Ann Allergy Asthma Immunol. 2012; 108: 123-4.
70. Matucci A, Pratesi S, Petroni G, Nencini F, Virgili G, Milla M, Maggi E, Vultaggio A. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy. 2013; 43: 659-64.
71. Kelsall J, Rogers P, Galindo G, De Vera MA. Safety of infliximab treatment in patients with rheumatoid arthritis in a real-world clinical setting: description and evaluation of infusion reactions. J Rheumatol. 2012; 39: 1539-45.
72. Wright RC. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol. 2003; 49: 160-1.
73. Chan JL, Davis-Reed L, Kimball AB. Counterregulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol. 2004; 3: 315-8.
74. Desai D, Goldbach-Mansky R, Milner JD, Rabin RL, Hull K, Pucino F, Colburn N. Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs. Ann Pharmacother. 2009; 43: 967-72.
75. Sendur OF, Turan Y, Berkit IK, Tastaban E. Angiooedema in a patient treated with etanercept for rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009; 104: 488-90.
76. Bavbek S, Aydi{dotless}n O, Ataman S, Cahill K, Castells M. Injection-site reaction toetanercept: role of skin test in the diagnosis of such reaction and successful desensitization. Allergy. 2011; 66: 1256-7.
77. Leloup P, Daviet V, Chiffoleau A, Dréno B. Urticaria pigmentosa after treatment with TNF antagonists: a case report. Arch Dermatol. 2011; 147: 1459-60.
78. Quismorio A, Brahmbhatt B, Houng M, Panush RS. Etanercept allergy and anaphylaxis. J Rheumatol. 2012; 39: 2225-6.
79. Tugnet N, Youssef A, Whallett AJ. Wells' syndrome (eosinophilic cellulitis) secondary to infliximab. Rheumatology (Oxford). 2012; 51: 195-6.
80. Crayne CB, Gerhold K, Cron RQ. Anaphylaxis to etanercept in two children with juvenile idiopathic arthritis. J Clin Rheumatol. 2013; 19: 129-31.
81. Miki H, Okamoto A, Ishigaki K, Sasaki O, Sumitomo S, Fujio K, Yamamoto K. Cardiopulmonary arrest after severe anaphylactic reaction to second infusion ofinfliximab in a patient with ankylosing spondylitis. J Rheumatol. 2011; 38: 1220.
82. Rosenstein RK, Panush RS, Kramer N, Rosenstein ED. Hypereosinophilia and Seroconversion of Rheumatoid Arthritis. Clin Rheumatol. 2014. In press. DOI 10. 1007/s10067-014-2566-6.
83. Quercia O, Emiliani F, Foschi FG, Stefanini GF. Adalimumab desensitization after anaphylactic reaction. Ann Allergy Asthma Immunol. 2011; 106: 547-8.
84. van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince FH, Kokke FT, Nieuwenhuis EE, Horneff G, Wulffraat NM. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2011; 38: 1441-6.
85. Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, Ganser G, Horneff G. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology (Oxford). 2012; 51: 1407-15.
86. Barrientos N, García-Sánchez S, Domínguez JD. Letter: Lichenoid eruption induced by etanercept. Dermatol Online J. 2012; 18: 15.
87. Pontikaki I, Shahi E, Frasin LA, Gianotti R, Gelmetti C, Gerloni V, Meroni PL. Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2012; 42: 131-4.
88. Chiriac A, Foia L, Chiriac AE, Ancuţa C, Manea P, Profire L, Filip F. Lichen planus secondary complications associated with the use of biologic therapy for rheumatoid arthritis. Rom J Morphol Embryol. 2013; 54: 829-31.
89. Fujikawa K, Kawakami A, Hayashi T, Iwamoto N, Kawashiri SY, Aramaki T, Ichinose K, Tamai M, Arima K, Kamachi M, Yamasaki S, Nakamura H, Ida H, Origuchi T, Eguchi K. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Mod Rheumatol. 2010; 20: 86-9.
90. Pàmies A, Castro S, Poveda MJ, Fontova R. Leucocytoclastic vasculitis associated with golimumab. Rheumatology (Oxford). 2013; 52: 1921-3.
91. Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc. 2012; 87: 739-45.
92. Parekh K, Ching D, Rahman MU, Stamp LK. Onset of Wegener's granulomatosis during therapy with golimumab for rheumatoid arthritis: a rare adverse event? Rheumatology (Oxford). 2010; 49: 1785-7.
93. Rolle AS, Zimmermann B, Poon SH. Etanerceptinduced Henoch-Schönlein purpura in a patient with ankylosing spondylitis. J Clin Rheumatol. 2013; 19: 90-3.
94. Cancelliere N, Barranco P, Vidaurrázaga C, Benito DM, Quirce S. Subacute prurigo and eosinophilia in a patient with rheumatoid arthritis receiving infliximab and etanercept. J Investig Allergol Clin Immunol. 2011; 21: 248-9.
95. Mounach A, Rezqi A, Nouijai A, Ghozlani I, Achemlal L, Maghraoui AE, Bezza A. StevensJohnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease. Rheumatol Int. 2013; 33: 1351-3.
96. Sawada Y, Nakamura M, Hama K, Hino R, Tokura Y. A high serum concentration of chemerin in pustular dermatitis paradoxically induced by etanercept. J Am Acad Dermatol. 2012; 66: e182-4.
97. Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitorassociated dermatomyositis. Arch Dermatol. 2010; 146: 780-4.
98. Liu SW, Velez NF, Lam C, Femia A, Granter SR, Townsend HB, VleugelsRA. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis. JAMA Dermatol. 2013; 149: 1204-8.
99. Ramírez J, Hernández MV, Galve J, Cañete JD, Sanmartí R. Morphea associated with the use of adalimumab: a case report and review of the literature. Mod Rheumatol. 2012; 22: 602-4.
100. Puertas-Abreu E, Polanco ER, Azocar M, Mundarain LA, Nuñez-Sotelo CM, Montaño R, Vivas FH, Noguera ZT, Marín F, Bellorin O, Rivas JG, Toro E, Benzaquen E, Rauseo M, Gutiérrez González LA. Onset of lupus like syndrome in patients with spondyloarthritis treated with antiTNF-α. Int Arch Med. 2012; 5: 7.
101. Vaz JL, Andrade CA, Pereira AC, Martins Mde F, Levy RA. Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus. Rev Bras Reumatol. 2013; 53: 358-64.
102. Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2009; 84: 979-84.
103. Vezzoli P, Violetti SA, Serini SM, Muratori S, Berti E, Crosti C. Cutaneous lupus erythematosus induced by adalimumab. J Dermatol. 2011; 38: 283-4.
104. Williams VL, Cohen PR. TNF alpha antagonistinduced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol. 2011; 50: 619-25.
105. Diaz JC, Vallejo S, Cañas CA. Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab. Rheumatol Int. 2012; 32: 3315-7.
106. Guerin M, Haettich B, Bara C, Artru L, Prophette B, Célérier P, Maillard H. Lupus attributable to antiTNF therapy and revealed by interstitial granulomatous dermatitis. Rheumatol Int. 2012; 32: 2937-40.
107. Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol. 2012; 39: 481-92.
108. Sifuentes Giraldo WA, Ahijón Lana M, García Villanueva MJ, González García C, Vázquez Diaz M. Chilblain lupus induced by TNF-αantagonists: a case report and literature review. Clin Rheumatol. 2012; 31: 563-8.
109. Santiago T, Santiago MG, Rovisco J, Duarte C, Malcata A, da Silva JA. A case of infliximabinduced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-α agent? Clin Rheumatol. 2013; 32: 1819-22.
110. Akgül O, Ki{dotless}li{dotless}ç G, Ki{dotless}li{dotless}ç E, Cüce I, Ozgöçmen S. A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept. Rheumatol Int. 2014; 34: 443-4.
111. Brunasso AM, Aberer W, Massone C. Subacute lupus erythematosus during treatment with golimumab for seronegative rheumatoid arthritis. Lupus. 2014; 23: 201-3.
112. Cemil BC, Atas H, Canpolat F, Akca Y, Sasmaz R. Infliximab-induced discoid lupus erythematosus. Lupus. 2013; 22: 515-8.
113. Almoallim H, Al-Ghamdi Y, Almaghrabi H, Alyasi O. Anti-Tumor Necrosis Factor-αInduced Systemic Lupus Erythematosus. Open Rheumatol J. 2012; 6: 315-9.
114. Joyau C, Veyrac G, Dixneuf V, Jolliet P. Antitumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol. 2012; 30: 700-6.
115. Nguyen K, Vleugels RA, Velez NF, Merola JF, Qureshi AA. Psoriasiform reactions to anti-tumor necrosis factor αtherapy. J Clin Rheumatol. 2013; 19: 377-81.
116. Teraki Y, Tanaka S, Hitomi K, Izaki S. A case of generalized psoriasiform and pustular eruption induced by infliximab: evidence for skin-homing Th17 in the pathogenesis. Br J Dermatol. 2010; 163: 1347-51.
117. Glenn CJ, Kobraei KB, Russo JJ. New-onset psoriasis associated with adalimumab: a report of two cases. Dermatol Online J. 2011; 17: 15.
118. Perman MJ, Lovell DJ, Denson LA, Farrell MK, Lucky AW. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children. Pediatr Dermatol. 2012; 29: 454-9.
119. Madigan LM, Kaffenberger BH, Wong HK. Bullae and psoriasiform hyperkeratosis after treatment with golimumab. J Am Acad Dermatol. 2013; 68: e195-6.
120. Shelling ML, Vitiello M, Lanuti EL, Miteva M, Romanelli P, Kerdel FA. A Case of Palmoplantar Pustulosis Induced by Certolizumab Pegol: New Anti-TNF-alpha Demonstrates the Same Class Effect. J Clin Aesthet Dermatol. 2012; 5: 40-1.
121. Sauder MB, Glassman SJ. Palmoplantar subcorneal pustular dermatosis following adalimumab therapy for rheumatoid arthritis. Int J Dermatol. 2013; 52: 624-8.
122. Boussemart L, Jacobelli S, Batteux F, Goulvestre C, Grange P, Carlotti A, Morini JP, Gorin I, Ziza JM, Avril MF, Dupin N. Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports. Dermatology. 2010; 221: 201-5.
123. Ratnarathorn M, Raychaudhuri SP, Naguwa S. Disseminated granuloma annulare: a cutaneous adverse effect of anti-tnf agents. Indian J Dermatol. 2011; 56: 752-4.
124. Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust. 2007; 187: 524-6.
125. Tobon GJ, Cañas C, Jaller JJ, Restrepo JC, Anaya JM. Serious liver disease induced by infliximab. Clin Rheumatol. 2007; 26: 578-81.
126. Becker H, Willeke P, Domschke W, Gaubitz M. Etanercept tolerance in a patient with previous infliximab-induced hepatitis. Clin Rheumatol. 2008; 27: 1597-8.
127. Harada K, Akai Y, Koyama S, Ikenaka Y, Saito Y. A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. Clin Rheumatol. 2008; 27: 1063-6.
128. Grasland A, Sterpu R, Boussoukaya S, Mahe I. Autoimmune hepatitis induced by adalimumab with successful switch to abatacept. Eur J Clin Pharmacol. 2012; 68: 895-8.
129. Nozaki K, Silver RM, Stickler DE, Abou-Fayssal NG, Giglio P, Kamen DL, Daniel R, Judson MA. Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci. 2011; 342: 352-5.
130. Hemmati I, Kur J. Adalimumab-associated antiphospholipid syndrome: a case report and review of the literature. Clin Rheumatol. 2013; 32: 1095-8.
131. Aithal GP. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol. 2011; 7: 139-50.
132. Deepak P, Stobaugh DJ, Sherid M, Sifuentes H, Ehrenpreis ED. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. Aliment Pharmacol Ther. 2013; 38: 388-96.
133. Seror R, Richez C, Sordet C, Rist S, Gossec L, Direz G, Houvenagel E, Berthelot JM, Pagnoux C, Dernis E, Melac-Ducamp S, Bouvard B, Asquier C, Martin A, Puechal X, Mariette X. Pattern of demyelination occurring during anti-TNF-αtherapy: a French national survey. Rheumatology (Oxford). 2013; 52: 868-74.
134. Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. 2013. In press. doi:10. 1136/annrheumdis-2013-204195.
135. Mercieca C, Vella N, Borg AA. Demyelination during anti-TNFαtherapy for ankylosing spondylitis. Mod Rheumatol. 2012; 22: 303-7.
136. Papadia M, Herbort CP. Infliximab-induced demyelination causes visual disturbance mistaken for recurrence of HLA-B27-related uveitis. Ocul Immunol Inflamm. 2010; 18: 482-4.
137. Lozeron P, Denier C, Lacroix C, Adams D. Longterm course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol. 2009; 66: 490-7.
138. Andreadou E, Kemanetzoglou E, Brokalaki Ch, Evangelopoulos ME, Kilidireas C, Rombos A, Stamboulis E. Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature. Case Rep Neurol Med. 2013; 2013: 671935.
139. Matsumoto T, Nakamura I, Miura A, Momoyama G, Ito K. New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review. Clin Rheumatol. 2013; 32: 271-5.
140. Alshekhlee A, BasiriK, Miles JD, Ahmad SA, Katirji B. Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists. Muscle Nerve. 2010; 41: 723-7.
141. Alentorn A, Albertí MA, Montero J, Casasnovas C. Monofocal motor neuropathy with conduction block associated with adalimumab in rheumatoid arthritis. Joint Bone Spine. 2011; 78: 536-7.
142. Solomon AJ, Spain RI, Kruer MC, Bourdette D. Inflammatory neurological disease in patients treated with tumor necrosisfactor alpha inhibitors. Mult Scler. 2011; 17: 1472-87.
143. Alvarez-Lario B, Prieto-Tejedo R, Colazo-Burlato M, Macarrón-Vicente J. Severe Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review. Clin Rheumatol. 2013; 32: 1407-12.
144. Defty H, Sames E, Doherty T, Hughes R. Case report of transverse myelitis in a patient receiving etanercept for rheumatoid arthritis. Case Rep Rheumatol. 2013; 2013: 728371.
145. Makol A, Grover M. Adalimumab induced mononeuritis multiplex in a patient with refractory rheumatoid arthritis: a case report. Cases J. 2008; 1: 287.
146. Faillace C, de Almeida JR, de Carvalho JF. Optic neuritis after infliximab therapy. Rheumatol Int. 2013; 33: 1101-3.
147. Cereda CW, Zecca C, Mazzucchelli L, Valci L, Staedler C, Bassetti CL, Gobbi C. Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy. Mult Scler. 2013; 19: 820-3.
148. Ekici B, Aydi{dotless}n K, Cantez S, Ergül Y, Tatli{dotless}B. Etanercept-induced encephalopathy in a 7-year-old child. Pediatr Neurol. 2011; 45: 271-3.
149. Garg N, Woltjer R, Hamilton B, Neuwelt EA, Rosenbaum JT. A 67-year-old woman receiving tumor necrosis factor αinhibitor therapy presenting with neurologic dysfunction. Arthritis Care Res (Hoboken). 2013; 65: 658-65.
150. Ryu YS, Park SH, Kim JM, Kim EJ, Lee J, Kwok SK, Ju JH, Kim HY. A case of leukoencephalopathy associated with adalimumab-treated rheumatoid arthritis and a review of literature. Rheumatol Int. 2012; 32: 3481-5.
151. Bellizzi A, Anzivino E, Rodio DM, Palamara AT, Nencioni L, Pietropaolo V. New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy. Clin Dev Immunol. 2013; 2013: 839719.
152. Palazzo E, Yahia SA. Progressive multifocal leukoencephalopathy in autoimmune diseases. Joint Bone Spine. 2012; 79: 351-5.
153. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 2012; 64: 3043-51.
154. Keene DL, Legare C, Taylor E, Gallivan J, Cawthorn GM, Vu D. Monoclonal antibodies and progressive multifocal leukoencephalopathy. Can J Neurol Sci. 2011; 38: 565-71.
155. Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. Arthritis Rheum. 2010; 62: 3191-5.
156. Graff-Radford J, Robinson MT, Warsame RM, Matteson EL, Eggers SD, Keegan BM. Progressive multifocal leukoencephalopathy in a patient treated with etanercept. Neurologist. 2012; 18: 85-7.
157. Bessissow T, Renard M, Hoffman I, Vermeire S, Rutgeerts P, Van Assche G. Review article: nonmalignant haematological complications of antitumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012; 36: 312-23.
158. Haroon M, Daly M, Harney S. Re-challenge with etanercept in patients with etanercept-induced neutropenia. Clin Rheumatol. 2012; 31: 151-5.
159. Wenham C, Gadsby K, Deighton C. Three significant cases of neutropenia with etanercept. Rheumatology (Oxford). 2008; 47: 376-7.
160. Ottaviani S, Cerf-Payrastre I, Kemiche F, Pertuiset E. Adalimumab-induced neutropenia in a patient with rheumatoid arthritis. Joint Bone Spine. 2009; 76: 312-3.
161. Datta K, Ghosh RK, Ghosh SM. Serious neutropenia following etanercept administration in a 62 years female patient of rheumatoid arthritis. J Assoc Physicians India. 2010; 58: 643-4.
162. Levälampi T, Korpela M, Vuolteenaho K, Moilanen E. Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment. Rheumatol Int. 2008; 28: 261-9.
163. Azevedo VF, Silva MB, Marinello DK, Santos FD, Silva GB. Leukopenia and thrombocytopenia induced by etanercept: two case reports and literature review. Rev Bras Reumatol. 2012; 52: 110-2.
164. Pathare SK, Heycock C, Hamilton J. TNFalpha blocker-induced thrombocytopenia. Rheumatology (Oxford). 2006; 45: 1313-4.
165. Theodoridou A, Kartsios C, Yiannaki E, Markala D, Settas L. Reversible T-large granular lymphocyte expansion and neutropenia associated with adalimumab therapy. Rheumatol Int. 2006; 27: 201-2.
166. Bes C, Yazici A, Soy M. Monoclonal anti-TNF antibodies can elevate hemoglobin level in patients with ankylosing spondylitis. Rheumatol Int. 2013; 33: 1415-8.
167. Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford). 2013; 52: 1845-55.
168. Szalay B, Acs L, Vásárhelyi B, Kovács L, Balog A. Successful use of tocilizumab in a patient with rheumatoid arthritis following severe pancytopenia during etanercept therapy. J Clin Rheumatol. 2011; 17: 377-9.
169. Martínez Santana V, Izquierdo Navarro M, Calleja Hernández MÁ, Sánchez Sánchez T, Sainz Gil M. Severe pancytopenia following etanercept administration in rheumatoid arthritis. Int J Rheum Dis. 2012; 15: e78-9.
170. Araki D, Fujii H, Matsumura M, Yamagishi M, Yachie A, Kawano M. Etanercept-induced lupus accompanied by hemophagocytic syndrome. Intern Med. 2011; 50: 1843-8.
171. Kaneko A, Hirano Y, Fujibayashi T, Hattori Y, Terabe K, Kojima T, Ishiguro N. Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice. Mod Rheumatol. 2013; 23: 466-77.
172. Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Tanaka Y, Yamanaka H, Fujii K, Yoshinaga T, Freundlich B, Suzukawa M. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011; 21: 343-51.
173. Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheumatol. 2007; 36: 172-8.
174. Shidara K, Hoshi D, Inoue E, Yamada T, Nakajima A, Taniguchi A, Hara M, Momohara S, Kamatani N, Yamanaka H. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod Rheumatol. 2010; 20: 280-6.
175. Pérez-Alvarez R, Pérez-de-Lis M, Díaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bové A, BritoZerón P, Bosch X, Ramos-Casals M. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011; 41: 256-64.
176. Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostör AJ. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases-a systematic literature review. Rheumatology (Oxford). 2011; 50: 2297-305.
177. Pearce F, Johnson SR, Courtney P. Interstitial lung disease following certolizumab pegol. Rheumatology (Oxford). 2012; 51: 578-80.
178. Glaspole IN, Hoy RF, Ryan PF. A case of certolizumab-induced interstitial lung disease in a patient with rheumatoid arthritis. Rheumatology (Oxford). 2013; 52: 2302-4.
179. Dias OM, Pereira DA, Baldi BG, Costa AN, Athanazio RA, Kairalla RA, Carvalho CR. Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis. J Bras Pneumol. 2014; 40: 77-81.
180. Tournadre A, Ledoux-Eberst J, Poujol D, Dubost JJ, Ristori JM, Soubrier M. Exacerbation of interstitial lung disease during etanercept therapy: Two cases. Joint Bone Spine. 2008; 75: 215-8.
181. Millar A, McKew J, Taggart A. Fatal fibrosing alveolitis with certolizumab. Rheumatology (Oxford). 2012; 51: 953-5.
182. Jeannin G, Mathieu S, Kemeny JL, Caillaud D, Soubrier M. Alveolar hemorrhage after infliximab therapy. Joint Bone Spine. 2010; 77: 189-90.
183. Khaja M, Menon L, Niazi M, Fuentes GD. Diffuse alveolar hemorrhage and acute respiratory distress syndrome during treatment of rheumatoid arthritis with etanercept. J Bronchology Interv Pulmonol. 2012; 19: 228-31.
184. Taki H, Kawagishi Y, Shinoda K, Hounoki H, Ogawa R, Sugiyama E, Tobe K. Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment. Rheumatol Int. 2009; 30: 275-6.
185. Yamazaki H, Isogai S, Sakurai T, Nagasaka K. A case of adalimumab-associated interstitial pneumonia with rheumatoid arthritis. Mod Rheumatol. 2010; 20: 518-21.
186. Komiya K, Ishii H, Fujita N, Oka H, Iwata A, Sonoda H, Kadota J. Adalimumab-induced interstitial pneumonia with an improvement of preexisting rheumatoid arthritis-associated lung involvement. Intern Med. 2011; 50: 749-51.
187. Horai Y, Miyamura T, Shimada K, Takahama S, Minami R, Yamamoto M, Suematsu E. Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease. J Clin Pharm Ther. 2012; 37: 117-21.
188. Dascalu C, Mrejen-Shakin K, Bandagi S. Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. J Clin Rheumatol. 2010; 16: 172-4.
189. Aithal GP. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol. 2011; 7: 139-50.
190. Cho SK, Oh IH, Park CK, Bae SC, Sung YK. Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis. Rheumatol Int. 2012; 32: 1055-7.
191. Efe C. Drug induced autoimmune hepatitis and TNF-αblocking agents: is there a real relationship? Autoimmun Rev. 2013; 12: 337-9.
192. Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M. Liver injury from tumor necrosis factor-αantagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013; 11: 558-564.
193. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, Anofrei A, Reed G, Calabrese L, Hooper M, Baumgartner S, Furst DE. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010; 69: 1612-7.
194. van Denderen JC, Blom GJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Elevated liver enzymes in patients with ankylosing spondylitis treated with etanercept. Clin Rheumatol. 2012; 31: 1677-82.
195. Titos Arcos JC, Hallal H, Robles M, Andrade RJ. Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis. Rev Esp Enferm Dig. 2012; 104: 282-4.
196. Saleem G, Li SC, MacPherson BR, Cooper SM. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al. Arthritis Rheum. 2001; 44: 1966-8.
197. Thiéfin G, Morelet A, Heurgué A, Diebold MD, Eschard JP. Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine. 2008; 75: 737-9.
198. Durel CA, Feurer E, Pialat JB, Berthoux E, Chapurlat RD, Confavreux CB. Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis. BMC Neurol. 2013; 13: 212.
199. Nozaki K, Judson MA. Neurosarcoidosis. Curr Treat Options Neurol. 2013; 15: 492-504.
200. Vargas DL, Stern BJ. Neurosarcoidosis: diagnosis and management. Semin Respir Crit Care Med. 2010; 31: 419-27.
201. Almodóvar R, Izquierdo M, Zarco P, Javier Quirós F, Mazzucchelli R, Steen B. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol. 2007; 25: 99-101.
202. Gifre L, Ruiz-Esquide V, Xaubet A, Gómez-Puerta JA, Hernández MV, Sanmartí R. Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. Arch Bronconeumol. 2011; 47: 208-12.
203. Farah M, Al Rashidi A, Owen DA, Yoshida EM, Reid GD. Granulomatous hepatitis associated with etanercept therapy. J Rheumatol. 2008; 35: 349-51.
204. Korsten P, Sweiss NJ, Nagorsnik U, Niewold TB, Gröne HJ, Gross O, Müller GA. Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab. Am J Kidney Dis. 2010; 56: e17-21.
205. Setoguchi S, Schneeweiss S, Avorn J, Katz JN, Weinblatt ME, Levin R, Solomon DH. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008; 156: 336-41.
206. Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D, Burgess M, Xie A, Braun MM. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. Rheumatology (Oxford). 2007; 46: 1688-93.
207. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of antitumor necrosis factor therapy. Am J Med. 2004; 116: 305-11.
208. Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum. 2008; 58: 667-77.
209. Lazzerini PE, Acampa M, Hammoud M, Maffei S, Capecchi PL, Selvi E, Bisogno S, Guideri F, Galeazzi M, Pasini FL. Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis. J Rheumatol. 2008; 35: 1958-65.
210. Szekanecz Z, Kerekes G, Soltész P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol. 2009; 5: 677-84.
211. Singh M, Diwan MM, Patel KC. A rare case of supraventricular tachycardia induced by Infliximab: a case report. Cases J. 2009; 2: 147.
212. Santos RC, Figueiredo VN, Martins LC, Moraes Cde H, Quinaglia T, Boer-Martins L, Ferreira-Melo SE, Yazbek MA, Bertolo M, Moreno H Jr. Infliximab reduces cardiac output in rheumatoid arthritis patients without heart failure. Rev Assoc Med Bras. 2012; 58: 698-702.
213. Synetos A, Toutouzas K, Aznaouridis K, Lerakis S, Stefanadis C. Dilated cardiomyopathy induced by anti-tumor necrosis factor. Int J Cardiol. 2009; 132: e26-7.
214. Castro Rocha FA, Silva FS Jr. Reversible heart failure in a patient receiving etanercept for ankylosing spondylitis. J Clin Rheumatol. 2010; 16: 81-2.
215. Keystone EC. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J Rheumatol. 2011; 38: 1552-62.
216. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295: 2275-85.
217. Wong AK, Kerkoutian S, Said J, Rashidi H, Pullarkat ST. Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a metaanalysis of published randomized controlled studies. Clin Rheumatol. 2012; 31: 631-6.
218. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis. 2006; 65: 617-22.
219. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008; 10: R45.
220. Moulis G, Sommet A, Béné J, Montastruc F, Sailler L, Montastruc JL, Lapeyre-Mestre M. Cancer risk of anti-TNF-αat recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS One. 2012; 7: e48991.
221. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007; 56: 2886-95.
222. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011; 20: 119-30.
223. Dunk AA, Walt RP, Jenkins WJ, Sherlock SS. Diclofenac hepatitis. Br Med J (Clin Res Ed). 1982; 284: 1605-6.
224. Babany G, Pessayre D, Benhamou JP. Hepatitis caused by diclofenac. Gastroenterol Clin Biol. 1983; 7: 316.
225. Lascar G, Grippon P, Lévy VG. Acute fatal hepatitis during treatment with diclofenac (Voltarène). Gastroenterol Clin Biol. 1984; 8: 881-2.
226. Helfgott SM, Sandberg-Cook J, Zakim D, Nestler J. Diclofenac-associated hepatotoxicity. JAMA. 1990; 264: 2660-2.
227. Purcell P, Henry D, Melville G. Diclofenac hepatitis. Gut. 1991; 32: 1381-5.
228. Ouellette GS, Slitzky BE, Gates JA, Lagarde S, West AB. Reversible hepatitis associated with diclofenac. J Clin Gastroenterol. 1991; 13: 205-10.
229. Lewis JH. Hepatic toxicity of nonsteroidal antiinflammatory drugs. Clin Pharm. 1984; 3: 128-38.
230. Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology. 1995; 22: 820-7.
231. Mazeika PK, Ford MJ. Chronic active hepatitis associated with diclofenac sodium therapy. Br J Clin Pract. 1989; 43: 125-6.
232. Schapira D, Bassan L, Nahir AM, Scharf Y. Diclofenac-induced hepatotoxicity. Postgrad Med J. 1986; 62: 63-5.
233. Breen EG, McNicholl J, Cosgrove E, McCabe J, Stevens FM. Fatal hepatitis associated with diclofenac. Gut. 1986; 27: 1390-3.
234. Sallie RW, McKenzie T, Reed WD, Quinlan MF, Shilkin KB. Diclofenac hepatitis. Aust N Z J Med. 1991; 21: 251-5.
235. Rostom A, Goldkind L, Laine L. Nonsteroidal antiinflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin Gastroenterol Hepatol. 2005; 3: 489-98.
236. Laine L, Goldkind L, Curtis SP, Connors LG, Yanqiong Z, Cannon CP. How common is diclofenac-associated liver injury? Analysis of 17, 289 arthritis patients in a long-term prospective clinical trial. Am J Gastroenterol. 2009; 104: 356-62.
237. Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E, Niro V, Andriulli A, Leandro G, Di Mario F, Dallapiccola B. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007; 133: 465-71.
238. Chang CH, Chen HC, Lin JW, Kuo CW, Shau WY, Lai MS. Risk of hospitalization for upper gastrointestinal adverse events associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study in Taiwan. Pharmacoepidemiol Drug Saf. 2011; 20: 763-71.
239. Harirforoosh S, Asghar H, Jamali F Adverse Effects of Nonsteroidal Anti-inflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 2013; 16(5): 821-47.
240. Jamali F. Arthritis is associated with cardiovascular disease in the users of analgesics and nonsteroidal anti-inflammatory drugs. Arch Intern Med. 2007 Nov 26; 167(21): 2371-2.
241. Harirforoosh S, Jamali F. Renal adverse effects of non-steroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009; 8(6): 669-81.
242. Neuman M, Nicar M. Apoptosis in ibuprofeninduced Stevens-Johnson syndrome. Transl Res. 2007; 149: 254-9.
243. Nanau RM, Neuman MG. Ibuprofen-induced hypersensitivity syndrome. Transl Res. 2010; 155: 275-93.
244. Nanau RM, Neuman MG. Ibuprofen: Associated Adverse Drug Reactions. In: Carter WC, Brown BR (Eds.). Ibuprofen: Clinical Pharmacology, Medical Uses and Adverse Effects. Nova Science Publishers. Hauppauge, NY. 2013: 233-274. Chapter ID 13467. ISBN 978-1-62618-659-0. https://www. novapublishers. com/catalog/product_in fo. php?products_id=41156.
245. Wilke WS, Mackenzie AH. Methotrexate therapy in rheumatoid arthritis. Current status. Drugs. 1986; 32: 103-13.
246. Kevat S, Ahern M, Hall P. Hepatotoxicity of methotrexate in rheumatic diseases. Med Toxicol Adverse Drug Exp. 1988; 3: 197-208.
247. Houtman PM, Jansen TL, Blanken R. Anaphylactic reaction in a patient with rheumatoid arthritis: a rare side effect of methotrexate with etanercept as a provoking factor? J Clin Rheumatol. 2006; 12: 321-2.
248. Rabinovitz, Van Thiel DH. Hepatotoxicity of nonsteriodal anti-inflammaotry drugs. AM J Gastroenterol 1992; 87: 1696-1704.
249. Zimmerman HJ: Hepatotoxicity. Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd Ed. Philadelphia Lippinott-Williams-Wilkins, 1999.
250. Zimmerman HJ: Effects of aspirin and acetaminophen on the liver. Arch Intern Med 1981; 141: 333-338.
251. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-9.
252. Bissell DM, Gores GJ, Laskin, DL, Hoofnagle, JH. Drug-induced liver injury: mechanisms and test systems. Hepatology 2001; 33: 1009-14.
253. Chitturi, S, George, J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis 2002; 22: 169-86.
254. Newman, M, Auerbach, R, Feiner, H, et al. The role of liver biopsies in psoriatic patients receiving longterm methotrexate treatment: Improvement in liver abnormalities after cessation of treatment. Arch Dermatol 1989; 125: 1218-25.
255. Fontana RJ, McCashland TM, Benner KJ, Appelman HD, Gunartanam N and the Acute Liver Failure study group. Acute liver failure associated with prolonged use of Bromfenac leading to liver transplantation. Liver Transplant and Surgery, 1999, 5, 6, 480-4.
256. Clements PJ, Davis J. Cytotoxic drugs: their clinical application to the rheumatic diseases. Semin Arthritis Rheum. 1986; 15: 231-54.